Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Summit Technology v. Chiron Technolas GmbH

This article was originally published in The Gray Sheet

Executive Summary

Summit Technology v. Chiron Technolas GmbH: Chiron Technolas appeals German court ruling that the firm's Keracor 116 and Schwind GmbH's Keratom ophthalmic excimer laser systems infringe a Summit patent ("The Gray Sheet" Sept. 4, p. 14). Chiron Technolas is prohibited from manufacturing, selling or using the laser systems in Germany following the posting of a bond by Summit that was necessary for enforcement of an injunction issued by the German court. In addition to the appeal, Chiron Technolas has also filed a nullity action with the German patent office, Summit states. Schwind also plans to file an appeal. Coherent, which distributes the Schwind laser, states that no interruptions in product availability are anticipated since its laser can be offered with a newly developed optical delivery system that does not infringe "whenever it becomes necessary to do so," Coherent states...

You may also be interested in...

Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention

Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.

US FDA Offers More Advice On Mid-Trial Changes For Pandemic-Impacted Studies

A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.

US Filing Eyed After Qurient's Novel TB Candidate Proves Mettle

South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts